




Marcus A Lawson1,2, Jennifer M Parrott3,4, Robert H McCusker1,2,5, Robert Dantzer6, Keith W Kelley1,2,5
and Jason C O’Connor3,4,7*
Abstract
Background: Activation of the tryptophan degrading enzyme indoleamine-2,3-dioxygenase 1 (IDO1) is associated
with the development of behavioral signs of depression. Systemic immune challenge induces IDO1 in both the
periphery and the brain, leading to increased circulating and brain concentrations of kynurenines. However,
whether IDO1 activity within the brain is necessary for the manifestation of depression-like behavior of mice
following a central immune challenge remains to be elucidated.
Methods: We investigated the role of brain IDO1 in mediating depression-like behavior of mice in response to
intracerebroventricular injection of saline or lipopolysaccharide (LPS, 10 ng).
Results: LPS increased the duration of immobility in the tail suspension test and decreased preference for a sucrose
solution. These effects were associated with an activation of central but not peripheral IDO1, as LPS increased brain
kynurenine but had no effect on plasma concentrations of kynurenine. Interestingly, genetic deletion or
pharmacological inhibition of IDO1, using 1-methyl-tryptophan, abrogated the reduction in sucrose preference
induced by intracerebroventricular LPS. 1-Methyl-tryptophan also blocked the LPS-induced increase in duration of
immobility during the tail suspension test.
Conclusions: These data indicate that activation of brain IDO1 is sufficient to induce depression-like behaviors of
mice in response to central LPS.
Background
Over the past several decades, a link between inflamma-
tion and neuropsychiatric disorders has been firmly
established at both the clinical and preclinical levels [1].
In depressed patients, many studies have reported an
association between elevated levels of peripheral inflam-
matory markers (for example, plasma IL-6 and C-reactive
protein) and symptoms of major depression [2,3]. Also,
peripheral inflammation induced by lipopolysaccharide
(LPS), in both human volunteers and rodent models,
precipitates significant changes in cognitive function,
mood and behavior [4-7]. Individuals suffering from neu-
rodegenerative diseases with a neuroinflammatory signa-
ture, such as multiple sclerosis [8], Huntington’s disease
[9], Parkinson’s disease [10] and Alzheimer’s disease [11],
also have increased prevalence of comorbid neuropsychi-
atric disturbances. A common factor in these processes is
the increased expression of proinflammatory cytokines in
the brain that may mediate the core neuropsychiatric and
neurovegetative symptoms of major depression [12].
Cytokines released within the brain can directly im-
pact neuron function, as evidenced by IL-1β-induced
and TNFα-induced changes in long-term potentiation
[13-15], but they can also act indirectly by stimulating
the production of neuroactive molecules that have been
associated with depression. In the last decade, increasing
interest has focused on the tryptophan degrading en-
zyme indoleamine-2,3-dioxygenase 1 (IDO1). During
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inflammation, IDO1 is the first and rate-limiting enzyme
in a metabolic cascade leading to increased levels of kyn-
urenine in the circulation and tissues. Moreover, increased
IDO1 enzymatic activity and elevated kynurenine concen-
tration levels have been correlated with inflammation-
associated depression [16-19]. Recent preclinical research
has demonstrated that pharmacological inhibition of IDO1
enzymatic activity or genetic deletion of IDO1 abrogates
inflammation-dependent behavioral changes that model
depression. This has been demonstrated in a murine model
of acute inflammation induced by peripheral LPS and in a
model of chronic inflammation induced by peripheral in-
fection with Bacille Calmette Guérin [7,20-22]. There is
already evidence that direct activation of central cytokine
signaling pathways by intracerebroventricular (ICV) admi-
nistration of TNFα, LPS or the human immunodeficiency
virus transactivator of transcription (Tat) can precipitate
the development of depression-like behavior in rodents
that is associated with upregulation of cytokines and IDO1
[23-25]. However, the causal role of brain IDO1 activation
in these models has not yet been established.
To explore the potential of brain kynurenine metab-
olism in driving inflammation-induced depression-like
behavior, we challenged mice with a single ICV injec-
tion of LPS. Central LPS precipitated depression-like
behaviors coupled with increased kynurenine concen-
trations and kynurenine:tryptophan ratio specifically
within the brain. In contrast, IDO1 knockout (KO) or
wild-type (WT) mice pretreated with 1-methyl-tryptophan
(1MT) were protected from developing LPS-induced
depression-like behavior compared with LPS-treated
WT controls. Taken together, these data indicate
that upregulation of brain IDO1 is sufficient for the




Male Balb/C mice (Charles Rivers Laboratories,
Wilmington, MA, USA), C57BL/6J (WT) mice and
IDO1 homozygous deficient (KO) mice (The Jackson La-
boratory, Bar Harbor, ME, USA) were individually housed
and provided with ad libitum access to chow (Teklad
8640, Harlan laboratories, Indianapolis, IN, USA) and
water. Mice were housed in a temperature-controlled and
humidity-controlled room maintained on a 12-hour re-
verse light/dark cycle. Mice were allowed to acclimate to
these conditions for at least 7 days before being implanted
with a guide cannula for mice (Plastics One, Roanoke, VA,
USA) placed stereotaxically to extend 1 mm dorsal to
the lateral ventricle, as previously described [25]. Cannuli
were placed at 1.5 mm lateral, 0.6 mm posterior, and
1.3 mm dorsal with respect to bregma. Guide cannulas
were kept clean and covered using a screw-on dummy
cannula (Plastics One). Mice were given 10 to 14 days to
recover from surgery prior to treatment. All procedures
performed on mice were in compliance with the National
Institutes of Health guidelines and were approved by the
Institutional Animal Care and Use Committees at both the
University of Texas Health Science Center at San Antonio
and the University of Illinois at Urbana-Champaign.
Treatments were administered at the onset of the dark
cycle. ICV injections were administered using a 10 μl
gas-tight syringe attached to internal injector cannulas
(Plastics One) that extended 1 mm beyond the tip of the
guide cannula, thus penetrating the lateral ventricle. All
mice received treatments in 1 μl injection volume over
a 1-minute time period followed by an additional 1-
minute delay to allow diffusion before removing the in-
jector cannula. Mice were injected ICV with either saline
(saline) or with LPS (10 ng/μl) from Escherichia coli
O127:B8 (Sigma Aldrich, St Louis, MO, USA) prepared in
saline. This dose of LPS has been previously demonstrated
to induce a transient sickness behavior response in mul-
tiple strains of mice that is resolved by 24 hours post ad-
ministration, and the dose was selected based on its ability
to induce depression-like behaviors that are temporally
distinct from the acute sickness behaviors [26-29].
Experiment 1: Intracerebroventricular administration of
LPS precipitates depressive-like behavior and upregulates
kynurenine metabolism specifically within the brain
Experiment 1 was performed in Balb/C mice to deter-
mine whether direct activation of the central innate im-
mune response was sufficient to trigger the development
of depression-like behaviors and to establish whether
ICV LPS increased kynurenine pathway metabolism spe-
cifically within the brain, as measured by the kynurenine:
tryptophan ratio. Twenty-four hours after receiving either
saline or LPS administration into the lateral ventricles,
depression-like behaviors were measured. After behavioral
testing, mice were rapidly euthanized in a carbon dioxide
chamber and laparotomized to facilitate blood collection
and vascular perfusion. Blood samples were collected from
the inferior vena cava. Immediately following blood collec-
tion, the chest was opened, a knick was made in the right
atrium and ~30 ml ice-cold heparinized saline was per-
fused via the left ventricle. Brains were then rapidly re-
moved and placed in a vial on dry ice. The brains were
stored at −80°C until processing. Brains were removed
from −80°C storage and pulverized with a ceramic mortar
and pestle chilled on dry ice to maintain the brains in a fro-
zen state. The brain powder was mixed to homogenize the
tissue and the powder was then aliquoted for analysis. The
purpose of this procedure was to divide the tissue equally
and negate potential effects of hemispheric differences
brought about by cannulation.
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Depression-like behavior
Two tests of depression-like behavior were utilized in each
study [30]. At 24 hours after treatment, mice were sub-
mitted to the tail suspension test (TST) using the Mouse
Tail Suspension Package (Med Associates, St Albans, VT,
USA) as previously described [31]. During the TST, mice
were suspended by their tail using adhesive medical tape
attached to a strain force gauge. Mice were tested for
10 minutes and were considered immobile when the force
was below a lower threshold that was determined for each
individual mouse.
To determine whether mice display signs of anhedonic
behavior, we utilized a two-bottle sucrose preference test.
Mice were given ad libitum access to drink from bottles
containing either water or 1% (C57BL6/J) or 2% (Balb/C)
sucrose solution for a 24-hour period. Immediately prior
to being placed on the home cage (immediately after treat-
ment) and 24 hours later, the bottles were weighed so that
the amount of each solution that was consumed could be
calculated. Preference was calculated by determining the
percentage of sucrose consumed divided by the total fluid
intake (sucrose intake/total fluid intake × 100).
HPLC methods
Homogenized brain and plasma samples were analyzed
for kynurenine and tryptophan using a Coulochem III
electrochemical detector paired with a model 5041 am-
perometric analytical cell fitted with a glassy carbon tar-
get electrode (Thermo Scientific Dionex, Bannockburn,
IL, USA), as previously described [7]. The mobile phase
(pH 4.6) consisted of 75 mM NaH2PO4, 25 μM ethyl-
enediamine tetraacetic acid, and 100 μl/l triethylamine
mixed into acetonitrile:water (6:94 v:v). Compounds of
interest were separated with a Hypersil ODS C18 analyt-
ical column (2.1 mm × 150 mm, 3 μM; Thermo Scien-
tific, West Palm Beach, FL, USA) and compared against
an external standard curve made fresh on each day of
analysis. Chromatograms were collected and analyzed
using EZ Chrom SI software (Agilent Technologies, Santa
Clara, CA, USA).
Experiment 2: Utilization of conventional genetic
knockout mice to examine the mechanistic role of IDO1
in ICV LPS-induced depression-like behaviors
Results from Experiment 1 demonstrated a clear associ-
ation between depression-like behaviors and brain kyn-
urenine metabolism following ICV LPS. To explore the
potential mechanistic role of IDO1 in mediating the
depression-like behavioral response to LPS, IDO1 KO
mice or their WT background strain controls (C57BL/6J)
were treated as described in Experiment 1. Depression-like
behaviors were also measured following the same protocols
as described above. To confirm temporal dissociation be-
tween the acute sickness behavior response and depression-
like behaviors 24 hours after ICV LPS, an open field test
was utilized to assess exploratory locomotor activity,
followed by perfusion and tissue collection to measure
steady-state mRNA expression of proinflammatory cyto-
kines within the brain.
Exploratory locomotor activity
Exploratory locomotor activity, measured as the distance
traveled by each mouse within a testing chamber, is a
preferred assessment of acute sickness behavior because
it reflects the mouse’s capacity and willingness to move
freely and to explore a novel environment. Additionally,
exploratory locomotor activity correlates tightly to LPS-
induced fever responses [32] and does not involve a
compensatory phase, such as recovery of lost body
weight. The open field chamber consisted of a 40 cm
(width) × 40 cm (length) × 30 cm (height) acrylic box
with opaque walls. The chamber floor was dimly illumi-
nated from overhead (3 to 10 lux). A 5-minute testing
session was video recorded, and the chamber was
cleaned with 70% isopropanol between mice. Video files
were analyzed using Ethovision XT 7 tracking software
(Noldus, Leesburg, VA, USA).
RNA isolation and real-time RT-PCR
RNA was isolated using the PureLink® RNA Mini Kit
(Life Technologies, Grand Island, NY, USA) according to
the manufacturer instructions. RNA purity and concen-
tration was measured spectrophotometrically using a
NanoVue spectrophotometer (GE Healthcare Biosciences,
Piscataway, NJ, USA). Reverse transcription was carried
out on 2 μg total RNA using a high-capacity cDNA RT kit
(Life Technologies) according to the manufacturer’s in-
structions. Real-time RT-PCR was performed over 40 cy-
cles using a CFX384™ Real-Time PCR Detection System
(Bio-Rad, Hercules, CA, USA) and prevalidated Taqman®
Gene Expression Assays (Life Technologies) for both target
and housekeeping control genes: GAPDH (Mm9999991
5_g1), IL-1β (Mm01336189_m1), TNFα (Mm00443258_
m1), and IL-6 (Mm00446190_m1). Data are expressed as
the relative fold change using the 2–ΔΔCt calculation
method as previously described [33].
Experiment 3: Effect of 1-methyl tryptophan on ICV
LPS-induced depression-like behaviors
To confirm the genotype × treatment interactions that
were apparent in Experiment 2, WT mice were adminis-
tered either (A) 1 μl saline, (B) 1 μg/μl 1MT, (C) 10 ng/μl
LPS or (D) a solution containing 1 μg/μl 1MT and 10 ng/ml
LPS. 1MT was prepared by dissolving in 1 N HCl, then
buffered using sodium hydroxide to pH 6.5 before being
diluted to the final treatment concentration in physio-
logical saline. The dose of 1MT used was based on the
average brain 1MT concentrations in mice implanted with
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a subcutaneous chronic release pellet [7,34]. Depression-
like behaviors were measured 24 hours post LPS as de-
scribed in Experiments 1 and 2.
Statistical analysis
Data were analyzed using Statview 5.0 statistical software
package (SAS Institute Inc., Cary, NC, USA) and are
represented as the mean ± standard error of the mean.
All measures were analyzed using a one-way or a two-way
analysis of variance in IDO KO and 1MT studies. When
the two-way interaction was significant (P <0.05), post-hoc
analysis using Fisher’s protected least-significant difference
test was employed to test for differences among means.
Results
Intracerebroventricular administration of LPS precipitates
the development of depression-like behaviors in mice
(Experiment 1A)
To confirm that central LPS induced a sickness response,
we measured the change in body weight. As expected,
Balb/c mice injected ICV with 10 ng LPS lost body weight
over a 24-hour period following treatment (F1,12 = 5.63,
P <0.05; Figure 1a). We further evaluated whether central
LPS induced depression-like behaviors. Sucrose preference
was measured during the 24-hour period following treat-
ment. LPS-treated mice displayed a significant decrease in
sucrose preference (F1,12 = 8.31, P <0.05; Figure 1b). Mice
were then submitted to the TST 24 hours after treatment.
LPS caused a significant increase in the duration of im-
mobility when compared with saline-treated control mice
(F1,12 = 16.18, P <0.01; Figure 1c).
Kynurenine to tryptophan ratio is increased in brain, but
not plasma, following ICV LPS treatment (Experiment 1B)
To determine whether LPS-induced depression-like behav-
ior was associated with increased levels of kynurenine or
an elevated kynurenine:tryptophan ratio, plasma and whole
brain samples were collected and analyzed. LPS-treated
mice exhibited elevated brain kynurenine concentra-
tions compared with saline-treated mice (F1,11 = 10.24,
P <0.01; Table 1), but there was no effect of LPS
on brain tryptophan concentrations. Further, elevated
brain kynurenine drove an increase in the kynurenine:
tryptophan ratio (F1,11 = 11.26, P <0.01). In contrast,
LPS treatment had no effect on the plasma kynurenine
concentration, tryptophan concentration or kynurenine:
tryptophan ratio compared with plasma from saline-
treated mice (Table 1).
IDO1 knockout mice maintain sucrose preference
following ICV LPS (Experiment 2A)
To determine whether IDO1 activity is required for cen-
tral LPS to induce depression-like behavior, we exam-
ined whether IDO1 KO mice or WT control mice
develop depression-like behavior. Similar to WT mice,
IDO1 KO mice experienced a reduction in body weight
following ICV LPS treatment (LPS main effect; F1,45 =
19.7, P <0.01; Figure 2a). However, while LPS precipi-
tated a significant 25% reduction in sucrose preference
in WT mice, IDO1 KO mice were entirely resistant
to the anhedonic effects of ICV LPS, compared with
controls (strain × LPS interaction; F3,44 = 9.18, P <0.01;
Figure 2b). In contrast, IDO1 KO mice were not
protected from the LPS-induced increase in immobility
during the TST (LPS main effect; F1,22 = 18.29, P <0.01;
Figure 2c). These data indicate that IDO1 KO mice ex-
hibit a similar behavioral response to LPS as WT mice
during the TST. However, IDO1 KO mice do not dis-
play reduced preference for sucrose solution implicat-
ing brain IDO1 as a critical mediator of the anhedonic
response following ICV LPS.
Figure 1 Lipopolysaccharide administered via intracerebroventricular injection induced body weight loss and depression-like behavior.
(a) Lipopolysaccharide (LPS; 10 ng) decreased body weight over a 24-hour period following treatment. (b) Sucrose preference was decreased by
intracerebroventricular LPS. (c) LPS increased tail suspension test (TST) immobility. Data are the average ± standard error of the mean. *P <0.05,
**P <0.01. n = 7 mice per group.
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Intracerebroventricular administration of lipopolysaccharide
induces expression of proinflammatory cytokines in the
brain at 24 hours, but exploratory locomotor activity is not
reduced (Experiment 2B)
To determine whether the genotype × LPS interaction on
depression-like behavior observed in Figure 2b was a con-
sequence of differential proinflammatory cytokine expres-
sion or sickness behavior response, we examined the
steady-state expression of IL-1β, TNFα and IL-6 in WT or
IDO1 KO mice following ICV LPS or saline administration.
Expression of IL-1β (LPS main effect; F1,15 = 9.71, P <0.01;
Figure 3a) and TNFα (LPS main effect; F1,15 = 5.50, P <0.05;
Figure 3b), but not IL-6 (Figure 3c), was significantly
upregulated 24 hours post ICV LPS in both WT mice and
IDO1 KO mice. Interestingly, while these proinflammatory
cytokines are typically associated with the LPS-induced
sickness behavior response, the total distance traveled
(Figure 3d) and the duration of time spent moving during
the open field test (Figure 3e) was not significantly different
between any group 24 hours after ICV LPS administration.
Together, these data indicate that the depressive-like behav-
ior of WT and IDO1 KO mice following ICV LPS is not
simply a manifestation of a differential recovery from LPS-
induced sickness behavior response.
Central 1-methyl-tryptophan treatment protected mice
from central lipopolysaccharide-induced depression-like
behavior (Experiment 3)
To further test our hypothesis that brain IDO1 activity is
necessary for developing depression-like behavior in re-
sponse to ICV LPS, WT C57BL/6J mice were treated
with ICV saline or 1MT concurrently with or without
LPS. The LPS reduced body weight 24 hours following
treatment in both saline mice and 1MT co-treated mice
(LPS main effect; F1,21 = 29.39, P <0.01; Figure 4a), indi-
cating that 1MT does not block the nonspecific sickness
response. Treatment with 1MT significantly attenuated
the anhedonic effects of LPS (1MT × LPS interaction;
F3,19 = 5.18, P <0.05; Figure 4b) although LPS decreased
the preference for sucrose solution of both saline-treated
mice and 1MT-treated mice (LPS main effect; F1,21 =
26.48, P <0.01; Figure 4b). As expected, LPS increased
the duration of immobility in the TST in saline-treated
control mice (Figure 4c). However, the duration of im-
mobility was unchanged following LPS in mice cotreated
with 1MT (1MT × LPS interaction; F3,19 = 6.43, P <0.05).
Interestingly, mice that were only treated with 1MT also
exhibited reduced TST immobility compared with con-
trol + saline-treated mice or control + LPS-treated mice
(P <0.01). Taken together, these data indicate that inhib-
iting IDO1 with 1MT does not protect mice from the
nonspecific sickness response; however, 1MT protected
mice from the development of depression-like behavior
following ICV LPS. These data support the hypothesis that
IDO1 in the brain is necessary for inducing depression-
like behavior following ICV LPS.






0.09 ± 0.03A 0.26 ± 0.04B
Tryptophan
(nmol/mg wet weight)
1.16 ± 0.27A 1.45 ± 0.09A
Kynurenine:tryptophan 0.07 ± 0.02A 0.19 ± 0.03B
Plasma
Kynurenine (μmol/l) 0.89 ± 0.1A 0.99 ± 0.1A
Tryptophan (μmol/l) 44.27 ± 1.84A 47.63 ± 3.46A
Kynurenine:tryptophan 0.020 ± 0.002A 0.021 ± 0.003A
Brain and plasma were collected for analysis of kynurenine and tryptophan
concentrations using HPLC. Data are average concentrations ± standard error
of the mean. Averages within rows with different uppercase superscript letters
are significantly different; P <0.05. n = 6 to 7 mice per group.
Figure 2 Mice deficient in indoleamine-2,3-dioxygenase are protected from intracerebroventricular lipopolysaccharide-induced
anhedonia. (a) Both wild-type (WT) and indoleamine-2,3-dioxygenase (IDO1) knockout (KO) mice had similar decreases in body weight in
response to intracerebroventricular (ICV) lipopolysaccharide (LPS, 10 ng). (b) IDO1 KO mice maintained sucrose preference following ICV LPS
treatment, but (c) had similarly increased tail suspension test (TST) immobility as WT mice. Data are average ± standard error of the mean. **P
<0.01. n = 6 to 12 mice per group.
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Discussion
Here we show that ICV LPS induced depression-like be-
havior associated with increased brain kynurenine concen-
trations. Our data also suggest that brain IDO1 activity is
an important regulator of depression-like behavior follow-
ing ICV LPS, since genetic deletion or pharmacological in-
hibition of brain IDO1 protected mice from LPS-induced
depression-like behavior.
Previous studies established 10 ng LPS as an ICV dose
sufficient to induce central IDO1 expression and transient
sickness followed by detectable depression-like behaviors
[29]. Importantly, we have now demonstrated that this
dose of LPS increases IDO1 activity specifically in the
brain, as there were no measurable changes in plasma
concentrations of kynurenine or tryptophan. Further,
ICV LPS induced depression-like behavior concurrent
Figure 3 Brain mRNA expression of proinflammatory cytokines, but not sickness behavior, is increased by intracerebroventricular
lipopolysaccharide. Both wild-type (WT) and indoleamine-2,3-dioxygenase (IDO1) knockout (KO) mice exhibit increased steady-state mRNA
expression of (a) IL-1β and (b) TNFα, but not of (c) IL-6 in the whole brain 24 hours post intracerebroventricular (ICV) lipopolysaccharide (LPS, 10 ng).
Exploratory locomotor activity measured by (d) distance traveled or (e) duration of time during the test spent moving were not different 24 hours after
ICV LPS. Data are average ± standard error of the mean. n = 4 to 5 mice per group.
Figure 4 1-Methyl-tryptophan protects mice from central lipopolysaccharide-induced depression-like behaviors. (a) Mice given 1-methyl-
tryptophan (1MT) or saline had similar decreases in body weight in response to central lipopolysaccharide (LPS, 10 ng). (b) 1MT-treated mice
maintained sucrose preference following intracerebroventricular LPS treatment and (c) were protected from LPS-induced increase in tail
suspension test (TST) immobility as in wild-type mice. Data are average ± standard error of the mean. *P <0.05, **P <0.01. n = 6 mice per group.
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with elevations in brain kynurenine, and IDO1 was re-
quired for this behavioral response. Our previous work
has demonstrated that IDO1 activation is necessary for
inflammation-induced depression-like behavior follow-
ing systemic immune challenge [7,21,22]. We have also
shown that increasing circulating kynurenine levels via
exogenous administration of kynurenine to naïve mice
is sufficient to induce depression-like behavior [7,22].
However the respective role of peripheral and brain
IDO1 in inflammation-induced depression-like behav-
ior was not assessed in these studies.
To determine whether activation of brain IDO1 is re-
quired for depression-like behavior, we selected a dose of
LPS that, when administered ICV, has no measured effect
on peripheral IDO1. We tested the behavioral effect of
this dose of LPS in WT mice and in mice whose IDO1
activation was blocked genetically or pharmacologically.
In a manner similar to what we previously observed fol-
lowing systemic LPS, ICV LPS elicited a nonspecific
sickness response in mice whose IDO1 activation
was blocked, as evidenced by body weight loss and
upregulation of proinflammatory cytokine expression
within the brain. However, IDO1 KO mice maintained
sucrose preference following ICV LPS, whereas WT
mice exhibited an anhedonia-like response character-
ized by reduced sucrose preference. In contrast, IDO1
KO mice were not protected from the LPS-induced in-
crease in immobility in the TST, although saline-treated
IDO1 KO mice tended to have reduced TST immobility
compared with WT mice. The lack of protection ob-
served in IDO1 KO mice during TST testing would in-
dicate that this behavior could be influenced by the
induction of other inflammatory mediators acting inde-
pendently of IDO1 activation.
Evidence exists indicating that cytokines can influence
depression-like behaviors independent of IDO1 expres-
sion. Our previous research examining the protective
effects of insulin-like growth factor (IGF)-I demon-
strated that ICV IGF-I, administered prior to LPS,
protected against LPS-induced increase in TST immobil-
ity [29]. However, when the potential protective benefit
of IGF-I was investigated in the sucrose preference test,
mice administered IGF-I prior to an LPS challenge were
not protected against LPS-induced anhedonia [29]. In
these studies, IGF-I decreased central proinflammatory
cytokine expression but did not attenuate the induction
of brain IDO1 expression. Noteworthy is our previous
demonstration that cytokine expression in IDO1 KO
mice is not different from that of WT mice following
peripheral LPS [7]. These findings suggest that elevated
cytokine expression may be necessary to precipitate
depression-like behavior in the TST in response to direct
neuroimmune challenge, and may be sufficient to drive
this behavioral phenotype through an IDO1-independent
mechanism. However, activation of the kynurenine path-
way may be necessary for central LPS to induce the anhe-
donic response, as both genetic and pharmacological
inhibition of IDO1 mitigated the anhedonia-like effects
of LPS.
An interesting paradox emerged in the present dataset;
complete genetic deletion of IDO1 protected mice from
the behavioral effects of LPS only in the sucrose preference
test. Meanwhile, administration of 1MT elicited an anti-
depressant effect in LPS-treated mice in both the sucrose
preference test and the TST. While still speculative, com-
pensatory expression of indoleamine-2,3-dioxygenase 2
(IDO2) or tryptophan 2,3-dioxygenase (TDO2) in the brain
might occur in IDO1 KO mice. Both IDO2 and TDO2 di-
vert tryptophan to the kynurenine pathway [35,36]. TDO2
and IDO2 transcript expression is increased in brain tissue
following administration of LPS at a time correlated with
the presence of depression-like behavior [31]. Moreover,
recent evidence has implicated a role of brain TDO2 in
anxiety-like behavior because genetic deletion of TDO2
provided anxiolytic effects assessed as an increased time
spent in open areas of the elevated plus maze and open
field tests [36]. For our model, however, it should be noted
that TDO2 activity is not impacted by the presence of
1MT, and therefore it is unlikely that TDO2 is compensat-
ing for decreased IDO1 activity and driving depression-like
behavior observed in the current studies. IDO2 could per-
haps be compensating for the loss of IDO1 in KO mice. In
Experiment 3, we utilized the nonselective racemic mixture
of 1MT. Although it remains controversial, various studies
have demonstrated that levo stereoisomer 1MT provides
significant inhibition of IDO1 and IDO2 activity [35], while
the dextro stereoisomer 1MT has little effect on IDO1 ac-
tivity but does inhibit IDO2 activity [35,37]. Even though it
is generally accepted that IDO1 has significantly greater en-
zymatic activity and probably contributes the majority of
increased kynurenine in our studies [35,38], our data sug-
gest that an IDO1-independent pathway is responsible for
depression-like behavior in the TST following ICV LPS.
The current data are also the first to show that 1MT
administered directly into the brain can protect against
inflammation-induced depression-like behaviors in a man-
ner comparable with previous studies using systemic 1MT
[7,21,22]. Our findings are also in agreement with a recent
publication from Dobos and colleagues showing that 1MT
reduced time of immobility in the forced swim test four
days after a 5 μg dose of ICV LPS was administered [23].
Worthy of note is that the experimental design of Dobos
and colleagues’ study was considerably different from the
design employed here. The dose of LPS used was 500
times larger than our dose, and the timing of behavioral
testing after LPS treatment was not the same. High-dose
LPS could cause cell death within the brain, and, as the
authors stated, probably invoked peripheral IDO1 activity
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[23]. Furthermore, we injected 1MT directly into the brain
while Dobos and colleagues administered 1MT subcutane-
ously via a chronic release pellet or via injections without
determining inhibitor concentrations within the brain.
Our studies were designed to directly investigate the ef-
fects of brain IDO1 activity on neuroinflammation-
dependent depression-like behavior.
Conclusions
Taken together, our data confirm that centrally adminis-
tered LPS induces depression-like behavior that occurs
concurrently with elevations in brain kynurenine concen-
trations. Although additional experiments are necessary to
fully determine the role that kynurenine metabolism plays
in mediating the behavioral effects of inflammation, our
data implicate IDO1 as an important component of cen-
tral LPS-induced depression-like behavior, specifically su-
crose preference. Other dioxygenases with activity similar
to IDO1, such as TDO2 and possibly IDO2, could play a
role in increasing kynurenine levels in response to central
LPS treatment to precipitate certain depression-like be-
haviors. Depression-like behaviors may be differentially
regulated by IDO1-dependent downstream kynurenine me-
tabolism and proinflammatory cytokines; warranting fur-
ther investigation into these possibilities.
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